An Endpoints panel at #JPM23 (Adrien Villez for Endpoints News)
January 4, 2024 07:00 AM EST
Editor's note

What we’re do­ing dif­fer­ent­ly at JP Mor­gan this year

Drew Armstrong

Executive Editor

Here we go again!

De­spite all the grip­ing (in­clud­ing by me!), I gen­uine­ly like the JP Mor­gan con­fer­ence. It’s a cul­mi­na­tion of ideas we’ve been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times